Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib

Published:2021-07-02 Issue:26 Volume:100 Page:e26449
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Wu Yonghui,Chen Huiguo,Guan Jiexia,Zhang Kai,Wu Weibin,Li Xiaojun,Zhang Jian

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference20 articles.

1. Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer;Li;Clin Drug Investig,2020

2. Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6;Wu;Lung Cancer,2020

3. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2020

4. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: a multicenter study from India;Patel;Curr Probl Cancer,2020

5. Results of PROFILE 1029, a Phase III comparison of first-line crizotinib versus Chemotherapy in East Asian Patients with ALK-positive advanced non-small cell lung cancer;Wu;J Thorac Oncol,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary Complications of Lung Cancer Treatment;Respiratory Medicine;2023

2. Ceritinib;Reactions Weekly;2021-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP